Nutraveris

Category 'INNOVATION'

Thursday, February 21, 2019
Category : NEWS, INGREDIENTS, INNOVATION, CLINICAL EVIDENCE | Author : experts | Comment : No Comments
Tags:

NOL, Nutraveris Online, the most efficient data solution to create, keep up-to-date and launch your products in the 28 EU member states, used for 10years by more than 500 industry leaders informs you:

 

This meta-analysis was performed with 17 randomized clinical trials and evaluated the effects of omega-3 supplementation among 3363 patients in the management of dry eye disease.

omega-3 supplementation

Compared with placebo, omega-3 fatty acid supplementation decreased dry eye symptoms (p < 0.001) and corneal fluorescein staining (p = 0.032), whereas it increased the breakup time (p < 0.001) and Schirmer test values (used to test the amount of tears) (p < 0.001). No evidence of publication bias was observed, and sensitivity analyses indicated the robustness of results obtained. Meta-regression analysis showed a higher improvement of dry eye symptoms and breakup time in studies conducted in India.

 

In conclusion, this meta-analysis provides evidence that omega-3 fatty acid supplementation significantly improves dry eye symptoms and signs in patients with dry eye disease. 

 

Giannaccare G, Pellegrini M, Sebastiani S, Bernabei F, Roda M, Taroni L, Versura P, Campos EC.Efficacy of Omega-3 Fatty Acid Supplementation for Treatment of Dry Eye Disease: A Meta-Analysis of Randomized Clinical Trials. Cornea. 2019 Jan 29.

 

This information has been sourced by NOL, a collaborative and complete tool which contains all Regulatory, Scientific and Marketing data

  • It solves all regulatory issues since it contains the required information on all ingredients authorized in the 28 European member states…on regulatory status, health claims, authority opinions
  • It protects your investments since it is updated in real time with reliable quality information analyzed and reviewed by our experts, available hotline.
  • It enables you to be the most responsive with monthly reports and live alerts and a personal use of the information with a report editing tool and customizable bookmarks.

With NOL let’s : 

  • Formulate new innovative products
  • Check if your already existing formulas are still compliant with the in force regulations
  • Adapt your existing formulas to the requirements of other European countries where you are willing to export them
  • Do scientific & regulatory & marketing monitoring which enable to anticipate the withdrawal of products, the safety issues, new interesting scientific studies, the arrival of new players on the market…

 

More information on www.nutraveris.com

Contact our Scientific & Regulatory experts at NUTRAVERIS

contact@nutraveris.com, +33 2 96 76 54 87

Thursday, February 7, 2019
Category : NEWS, INGREDIENTS, INNOVATION, CLINICAL EVIDENCE | Author : experts | Comment : No Comments
Tags:

NOL, Nutraveris Online, the most efficient data solution to create, keep up-to-date and launch your products in the 28 EU member states, used for 10years by more than 500 industry leaders informs you:

The effects of alpha lipoid acid (ALA) on plasma lipids remains unclear due to contradictory results obtained in clinical trials. To clarify the effects of ALA, this meta-analysis includes 12 randomized and controlled trials assessing the effects of ALA on lipid profile.

 

alpha lipoic acid

 

Results show that ALA reduces total cholesterol level in comparison to controls (Weight mean difference = -10.18 mg/dL, 95% CI: -16.16, -4.20 mg/dL, p = 0.001). A significant reduction in LDL-cholesterol has also been measured (WMD = -9.22 mg/dL, 95% CI: -18.28, -0.16 mg/dL, p = 0.001). However, no change in HDL-cholesterol has been measured. Regarding triglycerides, the analysis show no significant effect of ALA on triglycerides, except in a subgroup analysis based in health status (diabetic vs. diabetic) in which triglycerides were reduced in both populations.

 

Therefore, ALA reduce plasma lipids. However, the consequences of these changes has to be clarified, notably regarding cardiovascular diseases.

 

Haghighatdoost F, Hariri M. Does alpha-lipoic acid affect lipid profile? A meta-analysis and systematic review on randomized controlled trials. Eur J Pharmacol. 2019 Jan 8. pii: S0014-2999(19)30009-3.

 

This information has been sourced by NOL, a collaborative and complete tool which contains all Regulatory, Scientific and Marketing data

  • It solves all regulatory issues since it contains the required information on all ingredients authorized in the 28 European member states…on regulatory status, health claims, authority opinions
  • It protects your investments since it is updated in real time with reliable quality information analyzed and reviewed by our experts, available hotline.
  • It enables you to be the most responsive with monthly reports and live alerts and a personal use of the information with a report editing tool and customizable bookmarks.

With NOL let’s : 

  • Formulate new innovative products
  • Check if your already existing formulas are still compliant with the in force regulations
  • Adapt your existing formulas to the requirements of other European countries where you are willing to export them
  • Do scientific & regulatory & marketing monitoring which enable to anticipate the withdrawal of products, the safety issues, new interesting scientific studies, the arrival of new players on the market…

 

More information on www.nutraveris.com

Contact our Scientific & Regulatory experts at NUTRAVERIS

contact@nutraveris.com, +33 2 96 76 54 87

Thursday, January 31, 2019
Category : NEWS, INGREDIENTS, INNOVATION, CLINICAL EVIDENCE | Author : experts | Comment : No Comments
Tags:

NOL, Nutraveris Online, the most efficient data solution to create, keep up-to-date and launch your products in the 28 EU member states, used for 10years by more than 500 industry leaders informs you:

 

The aim of this observational study was to analyze the association between retinoid intake (total vitamin A, retinol, β-carotene, α-carotene, β-cryptoxanthin, lycopene, as wellas lutein and zeaxanthin) and self-reported gastrointestinal symptoms (daily number of bowel movements, and the presence of painful tenesmus, flatulence, and constipation) in Caucasian individuals in the remission phase of  ulcerative colitis.

To do so, 56 ulcerative colitis remission individuals were recruited and retinoid intakes were analyzed on the basis of three-day dietary records.

 

Box plots of lutein and zeaxanthin intake

Box plots of lutein and zeaxanthin intake in groups of individuals stratified by the analyzed symptoms of tenesmus, flatulence and constipation. (-) symptom not declared; (+) symptom declared.

 

Results showed that one in every seven individuals reported recurring constipation. Higher intake of lutein and zeaxanthin may lower the incidence of constipation (p = 0.013).

Authors concluded that the intake of retinoids other than lutein and zeaxanthin was not associated with the incidence of constipation or other gastrointestinal symptoms.

 

Głąbska D, Guzek D, Zakrzewska P, Lech G. Intake of Lutein and Zeaxanthin as a Possible Factor Influencing Gastrointestinal Symptoms in Caucasian Individuals with Ulcerative Colitis in Remission Phase. J Clin Med. 2019 Jan 11;8(1). pii: E77.

 

This information has been sourced by NOL, a collaborative and complete tool which contains all Regulatory, Scientific and Marketing data

  • It solves all regulatory issues since it contains the required information on all ingredients authorized in the 28 European member states…on regulatory status, health claims, authority opinions
  • It protects your investments since it is updated in real time with reliable quality information analyzed and reviewed by our experts, available hotline.
  • It enables you to be the most responsive with monthly reports and live alerts and a personal use of the information with a report editing tool and customizable bookmarks.

With NOL let’s : 

  • Formulate new innovative products
  • Check if your already existing formulas are still compliant with the in force regulations
  • Adapt your existing formulas to the requirements of other European countries where you are willing to export them
  • Do scientific & regulatory & marketing monitoring which enable to anticipate the withdrawal of products, the safety issues, new interesting scientific studies, the arrival of new players on the market…

 

More information on www.nutraveris.com

Contact our Scientific & Regulatory experts at NUTRAVERIS

contact@nutraveris.com, +33 2 96 76 54 87

Tuesday, January 29, 2019
Category : NEWS, INGREDIENTS, INNOVATION, CLINICAL EVIDENCE | Author : experts | Comment : No Comments
Tags:

NOL, Nutraveris Online, the most efficient data solution to create, keep up-to-date and launch your products in the 28 EU member states, used for 10years by more than 500 industry leaders informs you:

 

This randomized clinical trial aimed to evaluate the effect of isoflavone administration, either in conjunction with probiotic use or not, on the symptoms of genitourinary syndrome of menopause, and compare the effects with those of hormone therapy, in 60 postmenopausal women aged 40 to 60 years, for 16 weeks.

Probiotics improve the metabolism of isoflavones in menopausal women

Volunteers received oral isoflavone (150 mg dry extract of glycine max) alone or isoflavone plus probiotic (Lactobacillus acidophilus, Lactobacillus casei, Lactococcus lactis, Bifidobacterium bifidum, and Bifidobacterium lactis) or hormone therapy (1  mg estradiol and 0.5  mg norethisterone acetate).

 

There was a significant increase in the daidzein, glycitein, equol intermediate, and O-dimethylangolensin contents, after 16 weeks, in the isoflavone plus probiotic group. The vaginal health score increased in the isoflavone and hormone therapy groups.

 

Probiotics improved the metabolism of isoflavones after 16 weeks of treatment. However, the increase in the contents of isoflavones and their metabolites failed to yield an estrogenic effect on the urogenital tract and relieve the vulvovaginal symptoms.

 

Ribeiro AE, Monteiro NES, Moraes AVG, Costa-Paiva LH, Pedro AO. Can the use of probiotics in association with isoflavone improve the symptoms of genitourinary syndrome of menopause? Results from a randomized controlled trial. Menopause. 2018 Dec 10.

 

This information has been sourced by NOL, a collaborative and complete tool which contains all Regulatory, Scientific and Marketing data

  • It solves all regulatory issues since it contains the required information on all ingredients authorized in the 28 European member states…on regulatory status, health claims, authority opinions
  • It protects your investments since it is updated in real time with reliable quality information analyzed and reviewed by our experts, available hotline.
  • It enables you to be the most responsive with monthly reports and live alerts and a personal use of the information with a report editing tool and customizable bookmarks.

With NOL let’s : 

  • Formulate new innovative products
  • Check if your already existing formulas are still compliant with the in force regulations
  • Adapt your existing formulas to the requirements of other European countries where you are willing to export them
  • Do scientific & regulatory & marketing monitoring which enable to anticipate the withdrawal of products, the safety issues, new interesting scientific studies, the arrival of new players on the market…

 

More information on www.nutraveris.com

Contact our Scientific & Regulatory experts at NUTRAVERIS

contact@nutraveris.com, +33 2 96 76 54 87

Thursday, January 24, 2019
Category : NEWS, INGREDIENTS, INNOVATION, CLINICAL EVIDENCE | Author : experts | Comment : No Comments
Tags:

NOL, Nutraveris Online, the most efficient data solution to create, keep up-to-date and launch your products in the 28 EU member states, used for 10years by more than 500 industry leaders informs you:

 

The aim of this triple-blind, randomized placebo-controlled trial was to survey the effect of saffron supplementation on anti-HSP70, high-sensitivity C-reactive protein (hs-CRP) and spirometry test in patients with allergic asthma.

To do so, 80 patients with mild and moderate allergic asthma were randomized to receive either two capsules of saffron (100 mg/d) or placebo (control group) for 8 weeks.

 

Saffron supplementation in patients with allergic asthma

Within- and between-group comparisons of the changes from baseline to endpoint measures for hs-CRP and anti-HSP70 in saffron and placebo groups of asthmatic patients

Results showed that saffron significantly reduced the hs-CRP (p < 0.001) and anti-HSP70 (p < 0.001) concentrations compared to placebo. In spirometry test, forced expiratory volume in first second (FEV1), forced vital capacity (FVC), FEV1/FVC ratio and forced expiratory flow were 25-75%. (FEF 25-75) increased significantly in saffron in comparison to placebo group (p < 0.05).

Authors concluded that saffron supplementation in patients with allergic asthma decreased significantly anti-HSPs 70 and hs-CRP and also improved some spirometry test factors.

 

Hosseini SA, Zilaee M, Shoushtari MH, Ghasemi Dehcheshmeh M. An evaluation of the effect of saffron supplementation on the antibody titer to heat-shock protein (HSP) 70, hsCRP and spirometry test in patients with mild and moderate persistent allergic asthma: A triple-blind, randomized placebo-controlled trial. Respir Med. 2018 Dec; 145:28-34.

 

This information has been sourced by NOL, a collaborative and complete tool which contains all Regulatory, Scientific and Marketing data

  • It solves all regulatory issues since it contains the required information on all ingredients authorized in the 28 European member states…on regulatory status, health claims, authority opinions
  • It protects your investments since it is updated in real time with reliable quality information analyzed and reviewed by our experts, available hotline.
  • It enables you to be the most responsive with monthly reports and live alerts and a personal use of the information with a report editing tool and customizable bookmarks.

With NOL let’s : 

  • Formulate new innovative products
  • Check if your already existing formulas are still compliant with the in force regulations
  • Adapt your existing formulas to the requirements of other European countries where you are willing to export them
  • Do scientific & regulatory & marketing monitoring which enable to anticipate the withdrawal of products, the safety issues, new interesting scientific studies, the arrival of new players on the market…

 

More information on www.nutraveris.com

Contact our Scientific & Regulatory experts at NUTRAVERIS

contact@nutraveris.com, +33 2 96 76 54 87